Oral Antibiotics for Uncomplicated Typhoid Fever
For uncomplicated typhoid fever, azithromycin (20 mg/kg/day, maximum 1 g once daily for 7 days) is the recommended first-line oral antibiotic for both adults and children, with superior outcomes compared to fluoroquinolones and comparable efficacy to ceftriaxone but with lower relapse rates.
Treatment Algorithm Based on Resistance Patterns
First-Line Treatment: Azithromycin
- Dosing: 20 mg/kg/day (maximum 1 g) once daily for 7 days 1
- Rationale: Azithromycin demonstrates lower clinical failure rates (OR 0.48,95% CI 0.26-0.89) and shorter hospital stays compared to fluoroquinolones 1. Most critically, it shows dramatically lower relapse rates (OR 0.09,95% CI 0.01-0.70) compared to ceftriaxone 1
- Clinical performance: Fever clearance time averages 5.8 days, with clinical cure rates of 82-85% in recent trials 2, 3
- Resistance context: Remains effective even in regions with 88-93% multidrug resistance and nalidixic acid resistance 3, 4
Alternative Options Based on Susceptibility
For Fully Susceptible Strains (increasingly rare):
- Fluoroquinolones (ciprofloxacin, ofloxacin, gatifloxacin) remain WHO-recommended first-line 1
- However, clinical performance is inferior to azithromycin even when susceptible (cure rate 62-64% vs 82-85%) 2, 3
For Quinolone-Resistant Strains (now predominant in South Asia):
- Azithromycin remains first-line 1
- Oral cefixime (10 mg/kg twice daily, maximum 400 mg) is an alternative 1
- Important caveat: The 2026 ACT-South Asia trial definitively showed that adding cefixime to azithromycin provides NO additional benefit (treatment failure 5.1% in both groups, p=1.00) 5. This strongly supports azithromycin monotherapy for antimicrobial stewardship.
For Multidrug-Resistant (MDR) Strains:
Key Clinical Considerations
Why Azithromycin Outperforms Other Options
The evidence consistently demonstrates azithromycin's superiority stems from:
- Intracellular activity: Effectively targets Salmonella typhi within macrophages
- Reduced fecal carriage: Only 1.6% post-treatment carriage vs 19.4% with ofloxacin 3
- Shorter fever clearance: 5.8 days vs 7-8 days with fluoroquinolones 2, 3
- Lower relapse rates: 91% reduction compared to ceftriaxone 1
Common Pitfalls to Avoid
Do not combine azithromycin with cefixime: The 2026 ACT-South Asia trial (n=1,831) definitively showed no benefit to combination therapy 5. This is critical for antimicrobial stewardship.
Avoid fluoroquinolones as empiric therapy: Despite WHO 2012 guidelines listing them first-line 1, 93-96% of isolates in endemic regions now show nalidixic acid resistance 3, 4. Clinical cure rates are only 62-64% 2, 3.
Do not use shorter courses: All successful regimens used 7-day courses. Shorter durations have not been validated.
Recognize gatifloxacin limitations: While showing equivalent efficacy to azithromycin in some trials 4, one major trial was stopped early due to emerging high-level fluoroquinolone resistance 1.
Dosing Summary
| Antibiotic | Adult Dose | Pediatric Dose | Duration |
|---|---|---|---|
| Azithromycin (preferred) | 1 g once daily | 20 mg/kg once daily | 7 days |
| Cefixime (alternative) | 400 mg twice daily | 10 mg/kg twice daily | 7-14 days |
| Ciprofloxacin (if susceptible) | 500-750 mg twice daily | 20 mg/kg/day divided | 7-14 days |
Monitoring and Expected Response
- Fever clearance: Expect defervescence within 5-8 days with azithromycin
- Treatment failure indicators: Persistent fever ≥7 days, clinical deterioration, or complications warrant blood culture and susceptibility testing
- Follow-up: Assess at day 7 for clinical response; relapse typically occurs within 28 days (rare with azithromycin at <10%)
The 2024 WHO guidelines synthesizing the most recent evidence, combined with the 2026 ACT-South Asia trial results, provide the strongest support for azithromycin monotherapy as the optimal oral treatment for uncomplicated typhoid fever 1, 5.